Fondazione Policlinico Universitario Agostino Gemelli IRCCS: clinical-trial pipeline
Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the sponsor of 971 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 476 are not yet finished and 24 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials476
Phase 2/3 and 313
Countries19
New in 90 days24
Trials by phase
| Phase | Trials |
|---|---|
| Not applicable | 894 |
| Phase 2 | 32 |
| Phase 4 | 20 |
| Phase 3 | 11 |
| Phase 1/2 | 8 |
| Early phase 1 | 2 |
| Phase 1 | 2 |
| Phase 2/3 | 2 |
Trials by status
| Status | Trials |
|---|---|
| Unknown | 260 |
| Recruiting | 224 |
| Completed | 223 |
| Not yet recruiting | 184 |
| Active, not recruiting | 68 |
| Terminated | 5 |
| Withdrawn or not authorised | 5 |
| Suspended or halted | 2 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 285 |
| Women's health and obstetrics | 119 |
| Cardiovascular | 117 |
| Gastroenterology and liver | 102 |
| Infectious disease and vaccines | 89 |
| Rare and genetic diseases | 76 |
| Neurology | 66 |
| Metabolic and endocrine (diabetes, obesity) | 63 |
| Respiratory | 61 |
| Immunology and rheumatology | 46 |
| Musculoskeletal | 31 |
| Nephrology and urology | 27 |
Countries
| Country | Trials |
|---|---|
| Italy | 834 |
| Spain | 4 |
| United Kingdom | 4 |
| France | 3 |
| Netherlands | 2 |
| Argentina | 1 |
| Belgium | 1 |
| Brazil | 1 |
| Canada | 1 |
| China | 1 |
| Czechia | 1 |
| Germany | 1 |
| Ireland | 1 |
| Israel | 1 |
| India | 1 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-20 | New trial posted | Targeted Nutritional Intervention (HMB, Arginine, Glutamine) in Patients With Pancreatic… |
| 2026-10-19 | New trial posted | Artificial Intelligence Integration in Breast Cancer Screening: The ANIHTA Study |
| 2026-10-15 | New trial posted | Artificial Intelligence Software (Prostate Intelligence) for Detecting Clinically Signifi… |
| 2026-10-07 | New trial posted | ctDNA-guided Enfortumab Vedotin plus Pembrolizumab in Untreated Patients with Advanced Ur… |
| 2026-10-06 | New trial posted | Non-Invasive Assessment of Early Health Determinants in Children and Adolescents |
| 2026-09-29 | New trial posted | A Master Regulator of Lipid-Associated Macrophage Function in Cancer |
| 2026-09-29 | New trial posted | The Ophthalmic Artery Doppler Evaluation Prior to Labor Induction and Adverse Intrapartum… |
| 2026-09-29 | New trial posted | Abrocitinib Dose Tapering in Patients With Atopic Dermatitis |
| 2026-09-24 | New trial posted | GCP-R3 Clinical Practice Survey in Research Centers |
| 2026-09-23 | New trial posted | Retrospective Evaluation of Autonomic Activity Through Electrodermal Activity Measurement… |
| 2026-09-22 | New trial posted | Patients With Cryptogenic Hypertransaminasemia |
| 2026-09-18 | New trial posted | Selective Axillary Dissection After Neoadjuvant Chemotherap Yin Patients With Lymphnode-p… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT06640166 | Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Me… | Phase 2 | Active, not recruiting | Italy |
| NCT06685042 | Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases | Phase 1/2 | Recruiting | Italy |
| 2024-516542-19-00 | Searching simple biomarkers to phenotype type 2 diabetic patients and personalize their treatment | Phase 4 | Recruiting | Italy |
| 2024-518017-26-00 | Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy. DIAMOND… | Phase 2 | Active, not recruiting | Italy |
| 2024-516304-42-00 | Early recognition of progressive lung fibrosis in systemic rheumatic diseases: a characterization of the pulm… | Phase 2 | Active, not recruiting | Italy |
| 2023-504035-40-00 | MITO CERV4: Single arm phase II study on Pembrolizumab in pre neoplastic high grade HPV-related vulvar and ce… | Phase 2 | Not yet recruiting | Italy |
| 2024-516649-38-00 | Randomized phase III trial on NIraparib-Dostarlimab) vs physician’s choice CHEmotherapy in recurrent, ovarian… | Phase 3 | Active, not recruiting | Czechia, Germany, France, Italy |
| 2024-516632-99-00 | MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin… | Phase 2 | Active, not recruiting | Italy |
| NCT06820255 | DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer. | Phase 4 | Active, not recruiting | Italy |
| 2024-518847-40-00 | RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICEN… | Phase 2 | Active, not recruiting | Italy |
| 2024-518783-13-00 | Indocyanine green to assess vascularity of ileal conduit anastomosis and regulate ureteral resection margins… | Phase 2 | Recruiting | Italy |
| 2024-518939-12-00 | Single-cell deep phenotyping of B lymphocytes to personalize immunotherapy in patients with Myasthenia Gravis… | Phase 3 | Active, not recruiting | Italy |
| 2024-518937-26-00 | Efficacy and safety of the combination of Cisplatin plus Nab-paclitaxel and Nivolumab with radiotherapy after… | Phase 2 | Recruiting | Italy |
| 2024-518623-30-00 | RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abirateron… | Phase 4 | Recruiting | Italy |
| 2024-518938-81-00 | Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy with systemic Nabpaclitaxel-Gemcitabi… | Phase 2 | Recruiting | Italy |
| 2024-517679-18-00 | Effect of proton pump inhibitors on the structural integrity of endoscopic sleeve gastroplasty: a single-cent… | Phase 4 | Recruiting | Italy |
| 2024-517424-18-00 | Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant NSCLC according to TP53 mutational… | Phase 4 | Active, not recruiting | Italy |
| 2024-517789-41-00 | CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOT… | Phase 4 | Recruiting | Italy |
| 2023-508303-20-01 | Evaluation of p-glycoprotein alterations in treatment-resistant depression: a [18F]MC225 PET study | Phase 2 | Recruiting | Italy |
| 2024-519760-40-00 | Hepatic radiotherapy added to standard of care for the treatment of HLA A*02:01 positive Metastatic Uveal Mel… | Phase 2 | Recruiting | Italy |
| 2026-526857-33-00 | Prevention of venous thromboembolism in cirrhotic patients with hepatocellular carcinoma | Phase 2 | Not yet recruiting | Italy |
| 2026-527171-28-00 | ctDNA-guided Enfortumab Vedotin plus Pembrolizumab in Untreated Patients with Advanced Urothelial Carcinoma.… | Phase 4 | Not yet recruiting | Italy |
| NCT07702721 | Intraoperative Microscopic Assessment of Lymph Node Status in Gynecological Malignancies | Not applicable | Not yet recruiting | |
| NCT07607912 | Clinical, Oncological and Metabolic Effects of Pancreatic Mass Loss After Partial, Near-total and Total Pancr… | Not applicable | Not yet recruiting | |
| NCT06710028 | Trustworthy Artificial Intelligence for Improvement of Stroke Outcomes | Not applicable | Active, not recruiting | Belgium, Spain, Italy |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Fondazione Policlinico Universitario Agostino Gemelli IRCCS clinical trials: 476 open, 13 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/fondazione-policlinico-universitario-agostino-gemelli-irccs/, data as of 2026-10-25.